Budesonide 1mg orodispersible tablet twice daily (DrugBank: Budesonide)
9 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
66 | IgA腎症 | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 0 |
94 | 原発性硬化性胆管炎 | 0 |
95 | 自己免疫性肝炎 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
98 | 好酸球性消化管疾患 | 2 |
228 | 閉塞性細気管支炎 | 0 |
299 | 嚢胞性線維症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02493335 (ClinicalTrials.gov) | January 15, 2016 | 7/7/2015 | Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis | Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Budesonide 0.5mg orodispersible tablet twice daily;Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily | Dr. Falk Pharma GmbH | NULL | Active, not recruiting | 18 Years | 75 Years | All | 204 | Phase 3 | Germany |
2 | NCT02434029 (ClinicalTrials.gov) | November 11, 2015 | 30/4/2015 | Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis | Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Budesonide 1mg orodispersible tablet twice daily;Drug: Placebo orodispersible tablet twice daily | Dr. Falk Pharma GmbH | NULL | Completed | 18 Years | 75 Years | All | 88 | Phase 3 | Germany |